Back to Results
First PageMeta Content
4-Aminopyridine / Pyridines / Zolpidem / Chemistry / Amines / Organic chemistry


NDA[removed] – FDA Approved Labeling Text dated January 2013 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMPYRA safely and effectively. See full prescribing inf
Add to Reading List

Document Date: 2013-01-23 15:16:42

Open Document

File Size: 280,40 KB

Share Result on Facebook

City

Reference / /

Company

Acorda Therapeutics / /

Country

United States / Canada / /

Event

FDA Phase / /

Facility

store AMPYRA / The terminal / /

IndustryTerm

aqueous oral solution / chemical name / food / /

MedicalCondition

asthenia / back pain / severe allergic reactions / insomnia / Seizures AMPYRA / complex partial seizure / lymphoma / Anaphylaxis AMPYRA / disease / headache / seizures / nasopharyngitis / amnesia / Carcinogenesis / urinary tract infection / nausea / Anaphylaxis / balance disorder / seizure / pain / urticaria / angioedema / multiple sclerosis / hypersensitivity / Urinary Tract Infections Urinary tract infections / Urinary Tract Infections / dizziness / limbic encephalitis / memory loss / MS / constipation / confusional state / Back pain / paresthesia / status epilepticus / post-marketing period seizures / /

Organization

Oral administration / FDA / /

/

Position

Major / /

Product

Extended Release tablets / Single AMPYRA tablet / baclofen / A10 / polyethylene glycol / AMPYRA tablets / store / Dalfampridine / AMPYRA / /

Technology

Pharmacokinetics / Pharmacodynamics / MRI / /

URL

www.fda.gov/medwatch / /

SocialTag